Citations

Showing 10 of 108104 citations.

Abstract 185: Income Status And Receipt Of Sacubitril/valsartan For The Treatment Of Heart Failure
Swabe, Gretchen , Addison, Daniel , Mazimba, Sula , Mohammed, Selma F. , Johnson, Amber E , Essien, Utibe R. , Breathett, Khadijah , Brewer, LaPrincess C. , Magnani, Jared W.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | May 12, 2022 | Volume: 15 | Issue: Suppl_1 | Pages: No page available

10.1161/circoutcomes.15.suppl_1.185 Get It

Background: Outcomes in heart failure with reduced ejection fraction (HFrEF), are influenced by access and adherence to guideline directed medical therapy. Objective: To study the association between median annual household income and: (1) odds of receiving sacubitril/valsartan, a novel angiotensin receptor/neprilysin inhibitor (ARNI) therapy among insured patients with heart failure with reduced ejection fraction (HFrEF) and (2) medication adherence (measured as the proportion of days covered (PDC)). Hypothesis: lower income is associated with lower odds of receiving and adhering to ARNI among patients with HFrEF. Methods: Using Optum’s deidentified Clinformatics® Data Mart, patients with ≥ 2 diagnoses of HFrEF and ≥ 6 months of enrollment for follow up (2016-2020) were included. Covariates included age, race, ethnicity, sex, educational attainment, household net worth, geographical region and Elixhauser comorbidity index. Prescription for ARNI was defined by presence of a claim within 180 days. Adherence was defined as PDC ≥80%. We fit multivariable-adjusted logistic regression models and hierarchical logistic regression accounting for covariates. We also assessed for race-income interaction. Results: Among 322007 individuals with HFrEF diagnosis, 136,613 had ≥6 months of complete data. Of the patients eligible for ARNI, only 5.4% (7409/136613) received a claim within 180 days of HFrEF diagnosis. After adjusting for social and clinical factors, the odds were elevated for ARNI claim within 180 days of HFrEF diagnosis (OR=1.38, 95% CI: 1.27, 1.49) for the highest income category (>$100K) compared with the lowest (<$40K). After adjustment, income <$40k) was associated with a 47% higher odds of PDC<80% compared with income >$100K. Conclusions: Higher patient income is associated with increased likelihood of an ARNI claim within 180 days of HFrEF diagnosis, even after adjusting for socioeconomic and clinical factors. Future analyses are needed to determine other social factors associated with delay in ARNI initiation and long-term adherence.
Abstract 172: Disparities In Pcsk9 Inhibitor Initiation Among Patients With Peripheral Arterial Disease Or Cerebrovascular Disease: A Cohort Study Of 500,000 Patients With Atherosclerotic Vascular Disease.
Laforest, Sherry K, Bal, Simer, Elgudin, Yakov , Deo, Salil V. , McAllister, David , Altarabsheh, Salah E. , Sattar, Naveed , Pell, Jill P.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | May 12, 2022 | Volume: 15 | Issue: Suppl_1 | Pages: No page available

10.1161/circoutcomes.15.suppl_1.172 Get It

Background: Effective lipid lowering therapy reduces deaths due to atherosclerotic vascular disease (ASCVD). Proprotein convertase subtilsin/kexin type 9 inhibitor (PCSK9i) drugs have emerged as effective add-on therapy to lower low-density lipoprotein (LDL) levels. Although the use of PCSK9i is limited by cost, PCSK9i use in a low-cost healthcare system [Veteran Health Affairs (VHA)] is unknown. Methods: We queried a cohort of US Veterans with coronary artery disease (CAD), PAD or CeVD receiving outpatient care (January 2016 – December 2019) at 124 VHA medical centers to evaluate the initiation of PCSK9i. We fit a mixed effects logistic regression model [with results presented as odds ratio (OR)] to evaluate the association of social deprivation (assessed by median household income and community deprivation index), the patient’s primary diagnosis and VHA medical center enrollment with PCSK9i initiation. Findings: From 519,566 patients (median age 74 years), 337,766 (65%), 79,926 (15%) and 101,874 (20%) had CAD, PAD and CeVD. Among 2,115/519,566 (0.4%) initiated with PCSK9i therapy, 84.3% had CAD, while only 7.2% and 8.5% had PAD and CeVD respectively. PCSK9i initiation was lower in those earning $40,000 - $80,000 [OR 1.13 (1.01 – 1.27)] or > $80,000 [OR 1.41 (1.14 – 1.75)]. Even moderate community deprivation [OR 0.87 (0.77 – 0.97)] was associated with lower PCSK9i therapy. Compared to CAD patients, PAD [OR 0.50 (0.35 – 0.70)] and CeVD [OR 0.23 (0.15 – 0.37)] were less likely to receive PCSK9i. Interpretation: Despite low co-pay, PCSK9i initiation rates among US veterans, nationwide, is very low. PAD and CeVD patients are much less likely to receive PCSK9i therapy. Household income and community deprivation influence PCSK9i use.
Cracking the cryptic code in amyotrophic lateral sclerosis and frontotemporal dementia: Towards therapeutic targets and biomarkers
Akiyama, Tetsuya , Koike, Yuka , Petrucelli, Leonard , Gitler, Aaron D. , Gitler, Aaron D , Koike, Yuka

Mayo Clinic

Clinical and Translational Medicine | May 12, 2022 | Volume: 12 | Issue: 5 | Pages: No page available

10.1002/ctm2.818 | PMID 35567447 Get It

AbstractAmyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two devastating human neurodegenerative diseases. A hallmark pathological feature of both diseases is the depletion of the RNA‐binding protein TDP‐43 from the nucleus in the brain and spinal cord of patients. A major function of TDP‐43 is to repress the inclusion of cryptic exons during RNA splicing. When it becomes depleted from the nucleus in disease, this function is lost, and recently, several key cryptic splicing targets of TDP‐43 have emerged, including STMN2, UNC13A, and others. UNC13A is a major ALS/FTD risk gene, and the genetic variations that increase the risk for disease seem to do so by making the gene more susceptible to cryptic exon inclusion when TDP‐43 function is impaired. Here, we discuss the prospects and challenges of harnessing these cryptic splicing events as novel therapeutic targets and biomarkers. Deciphering this new cryptic code may be a touchstone for ALS and FTD diagnosis and treatment.
Gestational Age at Delivery and Neonatal Outcomes among Infants with Gastroschisis in the Children's Hospitals Neonatal Consortium (CHNC)
Riddle, Stefanie , Agarwal, Nidhi , Ahmad, Irfan , Bendel‐Stenzel, Ellen , Shepherd, Jennifer, Williams, Sadie, Jacobson, Elizabeth , Group, the Children's Hospitals Neonatal Consortium's Gastroschisis Focus, Bendel-Stenzel, Ellen, Acharya, Krishna , Zaniletti, Isabella , Group, the Children's Hospitals Neonatal Consortium's Gastroschisis Focus

Mayo Clinic

American Journal of Perinatology | May 12, 2022 | Volume: 41 | Issue: 06 | Pages: 756-763

10.1055/s-0042-1744510 | PMID 35553040 Get It

Objective The effect of gestational age (GA) on gastroschisis outcomes is unclear and delivery timing varies in practice. We aimed to correlate clinical outcomes of infants with gastroschisis and GA at delivery in the Children's Hospitals Neonatal Consortium (CHNC). Study Design This was a retrospective multicenter cohort study of infants with gastroschisis admitted to CHNC neonatal intensive care units (NICUs) from 2010 to 2016. Patients were categorized by GA: 32 to 346/7, 35 to 366/7, and ≥37 weeks. Respiratory and feeding interventions, mortality, length of stay, and common complications were compared. Results In 2021 for patients with gastroschisis, median GA at delivery was 36.3 weeks (interquartile range [IQR] 35.1, 37.3) and mean birth weight 2,425 g (IQR 2,100, 2,766). Overall mortality was low and there was no difference across GA groups. Infants <35 weeks' gestation had the greatest need for respiratory and feeding interventions. Complications such as medical necrotizing enterocolitis (NEC), cholestasis, and central line-associated blood stream infection were less common in infants ≥37 weeks. Feeding initiation and full feeds were earliest in term infants, compared with infants between 35 and 366/7 weeks, and longest in infants <35 weeks. Prematurity had a significant negative association with breast milk exposure. Enteral feeding tube support at discharge increased with prematurity. Compared with term, infants born between 35 and 366/7 weeks' gestation had a higher incidence of medical NEC and lower exposure to mother's milk at discharge but the need for respiratory interventions or tube feeding at discharge was similar. Conclusion Premature infants with gastroschisis had more neonatal complications including respiratory interventions, longer NICU stay, longer time to full enteral feeds, and higher need for tube feeds at discharge as compared with those delivered at term. Differences were greatest for those <35 weeks GA. While overall mortality remains low, these results provide additional information about GA at birth in gastroschisis, with no evidence of benefit from preterm delivery. Key Points
Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation
Gertz, Morie A. , Warsame, Rahma , Muchtar, Eli , Buadi, Frances, Dingli, David , Hayman, Suzanne R. , Kapoor, Prashant , Kourelis, Taxiarchis , Kumar, Shaji , Lacy, Martha Q. , Dispenzieri, Angela , Kumar, Shaji K , Hogan, William J , Gertz, Morie A , Muchtar, E , Dingli, David , Dispenzieri, Angela , Gonsalves, Wilson I. , Hogan, William J.

Mayo Clinic

Leukemia & Lymphoma | May 12, 2022 | Volume: 63 | Issue: 10 | Pages: 2422-2427

10.1080/10428194.2022.2074993 | PMID 35549799 Get It

Indicators for Substantial Neurological Recovery Following Elective Anterior Cervical Discectomy and Fusion
Sebastian, Arjun S. , Wagner, Scott C. , Morrissey, Patrick B. , Kaye, I. David , Hilibrand, Alan S. , Kepler, Christopher K. , Pinter, Zachariah W. , Vaccaro, Alexander R.

Mayo Clinic

Clinical Spine Surgery | May 12, 2022 | Volume: 35 | Issue: 9 | Pages: E698-E701

10.1097/bsd.0000000000001340 | PMID 35552290 Get It

Study Design: Retrospective cohort study. Objective: The purposes of this study were to determine the rate of improvement of significant preoperative weakness, identify risk factors for failure to improve, and characterize the motor recovery of individual motor groups. Summary of Background Data: While neck and arm pain reliably improve following anterior cervical discectomy and fusion (ACDF), the frequency and magnitude of motor recovery following ACDF remain unclear. Methods: We performed a retrospective review of patients undergoing 1–4-level ACDF at a single institution between September 2015 and June 2016. Patients were subdivided into 2 groups based upon the presence or absence of significant preoperative weakness, which was defined as a motor grade <4 in any single upper extremity muscle group. Clinical notes were reviewed to determine affected muscle groups, rates of motor recovery, and risk factors for failure to improve. Results: We identified 618 patients for inclusion. Significant preoperative upper extremity weakness was present in 27 patients (4.4%). Postoperatively, 19 of the affected patients (70.3%) experienced complete strength recovery, and 5 patients (18.5%) experienced an improvement in muscle strength to a motor grade ≥4. The rate of motor recovery postoperatively was 85.7% in the triceps, 83.3% in the finger flexors, 83.3% in the hand intrinsics, 50.0% in the biceps, and 25.0% in the deltoids. Risk factors for failure to experience significant motor improvement were the presence of myelomalacia (odds ratio: 28.9, P<0.01) and the performance of >2 levels of ACDF (odds ratio: 10.1, P<0.01). Conclusions: Patients with substantial preoperative upper extremity weakness can expect high rates of motor recovery following ACDF, though patients with deltoid weakness, myelomalacia, and >2 levels of ACDF are less likely to experience significant motor improvement.
Impact of racial disparities and insurance status in patients with bone sarcomas in the USA
Hu, Xianglin , Houdek, Matthew T. , Huang, Wending, Sun, Zhengwang , Sun, Yangbai , Yan, Wangjun , Houdek, Matthew T , Huang, Wending , Sun, Zhengwang , Sun, Yangbai , Yan, Wangjun , Fujiwara, Tomohiro , Chen, Lingxiao

Mayo Clinic

Bone & Joint Research | May 12, 2022 | Volume: 11 | Issue: 5 | Pages: 278-291

10.1302/2046-3758.115.bjr-2021-0258.r2 | PMID 35549518 Get It

Aims Socioeconomic and racial disparities have been recognized as impacting the care of patients with cancer, however there are a lack of data examining the impact of these disparities on patients with bone sarcoma. The purpose of this study was to examine socioeconomic and racial disparities that impact the oncological outcomes of patients with bone sarcoma. Methods We reviewed 4,739 patients diagnosed with primary bone sarcomas from the Surveillance, Epidemiology and End Results (SEER) registry between 2007 and 2015. We examined the impact of race and insurance status associated with the presence of metastatic disease at diagnosis, treatment outcome, and overall survival (OS). Results Patients with Medicaid (odds ratio (OR) 1.41; 95% confidence interval (CI) 1.15 to 1.72) and uninsured patients (OR 1.90; 95% CI 1.26 to 2.86) had higher risks of metastatic disease at diagnosis compared to patients with health insurance. Compared to White patients, Black (OR 0.63, 95% CI 0.47 to 0.85) and Asian/Pacific Islander (OR 0.65, 95% CI 0.46 to 0.91) were less likely to undergo surgery. In addition, Black patients were less likely to receive chemotherapy (OR 0.67, 95% CI 0.49 to 0.91) compared to White patients. In patients with chondrosarcoma, those with Medicaid had worse OS compared to patients with insurance (hazard ratio (HR) 1.65, 95% CI 1.06 to 2.56). Conclusion In patients with a bone sarcoma, the cancer stage at diagnosis varied based on insurance status, and racial disparities were identified in treatment. Further studies are needed to identify modifiable factors which can mitigate socioeconomic and racial disparities found in patients with bone sarcomas. Cite this article: Bone Joint Res 2022;11(5):278–291.
Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction
Zhu, Mojun , Foster, Nathan R. , Hartley, Christopher , Mounajjed, Taofic, Fruth, Briant, Beamer, Staci E. , Harrington, Susan M. , Pitot, Henry C., Sanhueza, Cristobal T., Feng, Yening , Herrmann, Joerg , Huang, Bing, Bekaii‐Saab, Tanios , Wigle, Dennis A. , Ahn, Daniel H. , Hallemeier, Chris L., Yoon, Harry H. , Salomao, Marcela A, Fruth, Briant F, Feng, Yening , McWilliams, Robert R , Huang, Bing Q, Ma, Wen Wee , Dong, Haidong , Wigle, Dennis, Blackmon, Shanda , Yoon, Harry H , Bekaii-Saab, Tanios S , Chen, Chunhua , Hartley, Christopher P , Salomao, Marcela , Kim, Yohan , McWilliams, Robert R. , Lucien, Fabrice , Wee, Wen , Dong, Haidong

Mayo Clinic

Clinical Cancer Research | May 12, 2022 | Volume: 28 | Issue: 14 | Pages: 3021-3031

10.1158/1078-0432.ccr-22-0413 | PMID 35552651 Get It

Abstract Purpose: This phase Ib/2 trial investigated pembrolizumab-containing trimodality therapy in patients with gastroesophageal junction (GEJ) adenocarcinoma. Patients and Methods: Patients with GEJ adenocarcinoma (cT1–3NanyM0) received neoadjuvant pembrolizumab-containing chemoradiation (CROSS regimen) followed by surgical resection and adjuvant pembrolizumab. The primary endpoints were tolerability in the first 16 patients and pathologic complete response [pCR (ypT0N0)]. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). An independent propensity-score-matched cohort (treated with CROSS without immunotherapy) was used for comparison. Exploratory analyses included immune biomarkers in the tumor microenvironment (TME) and plasma. Results: We enrolled 31 eligible patients, of whom 29 received all expected doses of neoadjuvant pembrolizumab and 28 underwent R0 resection. Safety endpoints were met. The primary efficacy endpoint was not met [7/31 (22.6%) achieved pCR]. Patients with high [i.e., combined positive score (CPS) ≥ 10] baseline expression of programmed death (PD)-L1 in the TME had a significantly higher pCR rate than those with low expression [50.0% (4/8) vs. 13.6% (3/22); P = 0.046]. Patients with high PD-L1 expression also experienced longer PFS and OS than propensity-score-matched patients. Among trial patients with PD-L1 CPS &lt; 10, unprespecified analysis explored whether extracellular vesicles (EV) could identify further responders: an elevated plasma level of PD-L1–expressing EVs was significantly associated with higher pCR. Conclusions: Adding pembrolizumab to trimodality therapy showed acceptable tolerability but did not meet the pre-specified pCR endpoint. Exploratory analyses suggested that high PD-L1 expression in the TME and/or on EVs may identify patients most likely to achieve tumor response.
Familial Recurrence Patterns in Congenitally Corrected Transposition of the Great Arteries: An International Study
Tortigue, Marine , Nield, Lynne E. , Karakachoff, Matilde , McLeod, Christopher J. , Belli, Emré , Babu‐Narayan, Sonya V. , Prigent, Solène , Conway, Miriam, Elder, Robert W. , Ladouceur, Magalie , Kowalik, Ewa , Kalfa, David , Mussa, Shafi, Hiippala, Anita , Temple, Joel , Abadir, Sylvia , Gloan, Laurianne Le , Lachaud, Matthias , Sanatani, Shubhayan , Thambo, Jean‐Benoît , Gronier, Céline, Charbonneau, Anne, Koutbi, Linda , Houeijeh, Ali , Combes, Nicolas , Duthoit, Guillaume, Hiel, Bérengère, Erickson, Christopher C. , Bonnet, Caroline , Hare, George F. Van , Dina, Christian , Fournier, Emmanuelle , Bloa, Mathieu Le , Pass, Robert H. , Liberman, Leonardo , Happonen, Juha-Matti, Perry, James C. , Romefort, Bénédicte, Benbrik, Nadir , Hauet, Quentin , Fraisse, Alain , Dubin, Anne M. , Ho, Siew Yen , Redon, Richard , Bacha, Emile , Elder, Robert W , Ladouceur, Magalie , Khairy, Paul , Kowalik, Ewa , Barron, David J , Sanatani, Shubhayan , Amedro, Pascal , Vaksmann, Guy , Ovaert, Caroline , Houeijeh, Ali , Combes, Nicolas , Maury, Philippe , Erickson, Christopher C , Van Hare, George F , Dina, Christian , Fournier, Emmanuelle , Le Bloa, Mathieu , Perry, James C , Benbrik, Nadir , Abrams, Dominic J , Dubin, Anne M , Ho, Siew Yen , Redon, Richard , Baruteau, Alban-Elouen , McLeod, Christopher J , Karakachoff, Matilde , Nield, Lynne E , Babu-Narayan, Sonya V , Belli, Emre , Boët, Angèle , Charbonneau, Anne, Maury, Philippe , Bonnet, Caroline, Karsenty, Clément , Gatzoulis, Michael Α. , Abrams, Dominic J. , Schott, Jean‐Jacques , Baruteau, Alban‐Elouen

Mayo Clinic

Circulation: Genomic and Precision Medicine | May 12, 2022 | Volume: 15 | Issue: 3 | Pages: No page available

10.1161/circgen.121.003464 | PMID 35549293 Get It

Background: Congenitally corrected transposition of the great arteries (ccTGA) is a rare disease of unknown cause. We aimed to better understand familial recurrence patterns. Methods: An international, multicentre, retrospective cohort study was conducted in 29 tertiary hospitals in 6 countries between 1990 and 2018, entailing investigation of 1043 unrelated ccTGA probands. Results: Laterality defects and atrioventricular block at diagnosis were observed in 29.9% and 9.3%, respectively. ccTGA was associated with primary ciliary dyskinesia in 11 patients. Parental consanguinity was noted in 3.4% cases. A congenital heart defect was diagnosed in 81 relatives from 69 families, 58% of them being first-degree relatives, including 28 siblings. The most prevalent defects in relatives were dextro-transposition of the great arteries (28.4%), laterality defects (13.6%), and ccTGA (11.1%); 36 new familial clusters were described, including 8 pedigrees with concordant familial aggregation of ccTGA, 19 pedigrees with familial co-segregation of ccTGA and dextro-transposition of the great arteries, and 9 familial co-segregation of ccTGA and laterality defects. In one family co-segregation of ccTGA, dextro-transposition of the great arteries and heterotaxy syndrome in 3 distinct relatives was found. In another family, twins both displayed ccTGA and primary ciliary dyskinesia. Conclusions: ccTGA is not always a sporadic congenital heart defect. Familial clusters as well as evidence of an association between ccTGA, dextro-transposition of the great arteries, laterality defects and in some cases primary ciliary dyskinesia, strongly suggest a common pathogenetic pathway involving laterality genes in the pathophysiology of ccTGA.
The role of chemotherapy in metastatic prostate cancer
Sweeney, Christopher J. , Sweeney, Christopher , Riaz, Irbaz Bin

Mayo Clinic

Current Opinion in Urology | May 12, 2022 | Volume: 32 | Issue: 3 | Pages: 292-301

10.1097/mou.0000000000000985 | PMID 35552310 Get It

Purpose of review To summarize the role of chemotherapy and offer some guidance regarding the selection of chemotherapy in mPC. Recent findings Patients with mHSPC have varied prognoses with testosterone suppression alone (androgen deprivation therapy, ADT) and differential responses to docetaxel with ADT. Patients with de novo and metachronous high-volume disease have a robust survival benefit with the addition of docetaxel to hormonal therapies. Patients with synchronous low-volume disease have a more modest survival benefit from docetaxel and there is no evidence of survival benefit with docetaxel in patients with metachronous low-volume disease. Integration of biomarkers may refine treatment selection regardless of volume of disease. Docetaxel and cabazitaxel also impart an OS benefit in patients with metastatic castration-resistant prostate cancer (mCRPC). The choice of chemotherapy in mCRPC depends on treatment received in mHSPC setting. Docetaxel remains the first line chemotherapy in castration-resistant patients who have not received it in mHSPC followed by cabazitaxel, otherwise cabazitaxel can be deployed without docetaxel retreatment. Summary Chemotherapy is a key class of therapy for selected patients with mHSPC and mCRPC.